A physician-initiated double-blind, randomised, placebo-controlled , phase 2 study evaluating the efficacy and safety of inhibition of NADPH Oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2018
At a glance
- Drugs GKT 831 (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- 25 May 2018 Status changed from not yet recruiting to recruiting.
- 26 Oct 2017 According to a GenKyoTex media release, the company is on track to enroll the first patient by the end of 2017.
- 21 Jul 2017 New trial record